TY - JOUR
PY - 2022//
TI - Screening for obstructive sleep apnea in adults: US Preventive Services Task Force Recommendation Statement
JO - JAMA journal of the American Medical Association
A1 - Mangione, Carol M.
A1 - Barry, Michael J.
A1 - Nicholson, Wanda K.
A1 - Cabana, Michael
A1 - Chelmow, David
A1 - Rucker Coker, Tumaini
A1 - Davidson, Karina W.
A1 - Davis, Esa M.
A1 - Donahue, Katrina E.
A1 - Jaén, Carlos Roberto
A1 - Kubik, Martha
A1 - Li, Li
A1 - Ogedegbe, Gbenga
A1 - Pbert, Lori
A1 - Ruiz, John M.
A1 - Stevermer, James
A1 - Wong, John B.
SP - 1945
EP - 1950
VL - 328
IS - 19
N2 - IMPORTANCE: Current prevalence of obstructive sleep apnea (OSA) in the US is not well established; however, based on cohort and survey data, in 2007-2010 the estimated prevalence of at least mild OSA (defined as an apnea-hypoxia index [AHI] ≥5) plus symptoms of daytime sleepiness among adults aged 30 to 70 years was 14% for men and 5% for women, and the estimated prevalence of moderate to severe OSA (defined as AHI ≥15) was 13% for men and 6% for women. Severe OSA is associated with increased all-cause mortality. Other adverse health outcomes associated with untreated OSA include cardiovascular disease and cerebrovascular events, type 2 diabetes, cognitive impairment, decreased quality of life, and motor vehicle crashes.
OBJECTIVE: To update its 2017 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for OSA in adults. POPULATION: Asymptomatic adults (18 years or older) and adults with unrecognized symptoms of OSA. EVIDENCE ASSESSMENT: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in the general adult population. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in the general adult population. (I statement).
Language: en
LA - en SN - 0098-7484 UR - http://dx.doi.org/10.1001/jama.2022.20304 ID - ref1 ER -